Kimal launches Celt ACD femoral artery closure device

Kimal has introduced a new device for use in femoral artery closure called Celt ACD.

Launched at the recent EuroPCR industry conference in Paris, the unit has received CE Mark approval and is currently being assessed by the US Food and Drug Administration.

Key benefits of the Celt ACD include its ability to deliver almost immediate haemostasis, even in anticoagulated patients, as well as its simplicity and ease of use.

Because there is no need to change the introducer sheath used during the procedure, it allows a medical-grade stainless steel implant to be fitted in only three steps.

Immediate re-access is possible if required as the Celt ACD implant is clearly visible under fluoroscopy – unlike absorbable devices – while it also performs strongly in terms of minimising risks posed by calcification, high sticks and side sticks.

The manufacturer said delegates at EuroPCR "were excited to see this novel new product which offers numerous advantages over alternatives currently available".